Drug intelligence / Profile preview

amikacin + penicillin

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Regional Perfusion

Overview

A combination antibiotic therapy consisting of amikacin (an aminoglycoside) and penicillin (a beta-lactam). This combination leverages synergistic effects to treat various bacterial infections, particularly severe gram-negative infections. Amikacin works by blocking bacterial protein synthesis by binding to the 30S ribosomal subunit, while penicillin inhibits bacterial cell wall synthesis. The combination has shown efficacy in treating serious infections including septicemia, particularly in immunocompromised patients.

Other names: amikacin plus penicillin GAmik-Pen

Targets

PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on amikacin + penicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amikacin + penicillin.

Explore the full profile